rs572846

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_003793.4(CTSF):​c.1401T>C​(p.Arg467Arg) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.544 in 1,613,410 control chromosomes in the GnomAD database, including 244,359 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.61 ( 29741 hom., cov: 33)
Exomes 𝑓: 0.54 ( 214618 hom. )

Consequence

CTSF
NM_003793.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:11

Conservation

PhyloP100: -1.01

Publications

32 publications found
Variant links:
Genes affected
CTSF (HGNC:2531): (cathepsin F) Cathepsins are papain family cysteine proteinases that represent a major component of the lysosomal proteolytic system. Cathepsins generally contain a signal sequence, followed by a propeptide and then a catalytically active mature region. The very long (251 amino acid residues) proregion of the cathepsin F precursor contains a C-terminal domain similar to the pro-segment of cathepsin L-like enzymes, a 50-residue flexible linker peptide, and an N-terminal domain predicted to adopt a cystatin-like fold. The cathepsin F proregion is unique within the papain family cysteine proteases in that it contains this additional N-terminal segment predicted to share structural similarities with cysteine protease inhibitors of the cystatin superfamily. This cystatin-like domain contains some of the elements known to be important for inhibitory activity. CTSF encodes a predicted protein of 484 amino acids which contains a 19 residue signal peptide. Cathepsin F contains five potential N-glycosylation sites, and it may be targeted to the endosomal/lysosomal compartment via the mannose 6-phosphate receptor pathway. The cathepsin F gene is ubiquitously expressed, and it maps to chromosome 11q13, close to the gene encoding cathepsin W. [provided by RefSeq, Jul 2008]
CTSF Gene-Disease associations (from GenCC):
  • adult neuronal ceroid lipofuscinosis
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • neuronal ceroid lipofuscinosis 13
    Inheritance: AR, Unknown Classification: DEFINITIVE, STRONG, SUPPORTIVE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics, Genomics England PanelApp

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
BP6
Variant 11-66563987-A-G is Benign according to our data. Variant chr11-66563987-A-G is described in ClinVar as Benign. ClinVar VariationId is 259168.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-1.01 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.817 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CTSFNM_003793.4 linkc.1401T>C p.Arg467Arg synonymous_variant Exon 13 of 13 ENST00000310325.10 NP_003784.2 Q9UBX1
CTSFXM_011545328.3 linkc.1221T>C p.Arg407Arg synonymous_variant Exon 13 of 13 XP_011543630.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CTSFENST00000310325.10 linkc.1401T>C p.Arg467Arg synonymous_variant Exon 13 of 13 1 NM_003793.4 ENSP00000310832.5 Q9UBX1

Frequencies

GnomAD3 genomes
AF:
0.609
AC:
92535
AN:
151964
Hom.:
29684
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.824
Gnomad AMI
AF:
0.430
Gnomad AMR
AF:
0.446
Gnomad ASJ
AF:
0.528
Gnomad EAS
AF:
0.531
Gnomad SAS
AF:
0.395
Gnomad FIN
AF:
0.634
Gnomad MID
AF:
0.544
Gnomad NFE
AF:
0.539
Gnomad OTH
AF:
0.579
GnomAD2 exomes
AF:
0.521
AC:
130253
AN:
250108
AF XY:
0.518
show subpopulations
Gnomad AFR exome
AF:
0.826
Gnomad AMR exome
AF:
0.327
Gnomad ASJ exome
AF:
0.544
Gnomad EAS exome
AF:
0.547
Gnomad FIN exome
AF:
0.634
Gnomad NFE exome
AF:
0.543
Gnomad OTH exome
AF:
0.516
GnomAD4 exome
AF:
0.537
AC:
784612
AN:
1461328
Hom.:
214618
Cov.:
81
AF XY:
0.534
AC XY:
388057
AN XY:
726968
show subpopulations
African (AFR)
AF:
0.839
AC:
28084
AN:
33474
American (AMR)
AF:
0.342
AC:
15267
AN:
44704
Ashkenazi Jewish (ASJ)
AF:
0.537
AC:
14033
AN:
26132
East Asian (EAS)
AF:
0.511
AC:
20298
AN:
39688
South Asian (SAS)
AF:
0.402
AC:
34647
AN:
86234
European-Finnish (FIN)
AF:
0.631
AC:
33496
AN:
53090
Middle Eastern (MID)
AF:
0.516
AC:
2955
AN:
5722
European-Non Finnish (NFE)
AF:
0.542
AC:
603137
AN:
1111908
Other (OTH)
AF:
0.542
AC:
32695
AN:
60376
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.470
Heterozygous variant carriers
0
24159
48318
72478
96637
120796
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
17066
34132
51198
68264
85330
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.609
AC:
92641
AN:
152082
Hom.:
29741
Cov.:
33
AF XY:
0.605
AC XY:
44967
AN XY:
74340
show subpopulations
African (AFR)
AF:
0.825
AC:
34214
AN:
41490
American (AMR)
AF:
0.446
AC:
6821
AN:
15292
Ashkenazi Jewish (ASJ)
AF:
0.528
AC:
1830
AN:
3468
East Asian (EAS)
AF:
0.531
AC:
2738
AN:
5160
South Asian (SAS)
AF:
0.396
AC:
1910
AN:
4826
European-Finnish (FIN)
AF:
0.634
AC:
6710
AN:
10578
Middle Eastern (MID)
AF:
0.548
AC:
161
AN:
294
European-Non Finnish (NFE)
AF:
0.539
AC:
36657
AN:
67960
Other (OTH)
AF:
0.575
AC:
1210
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1766
3532
5299
7065
8831
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
746
1492
2238
2984
3730
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.573
Hom.:
37938
Bravo
AF:
0.607
Asia WGS
AF:
0.491
AC:
1709
AN:
3478
EpiCase
AF:
0.541
EpiControl
AF:
0.540

ClinVar

Significance: Benign
Submissions summary: Benign:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Neuronal ceroid lipofuscinosis 13 Benign:4
Apr 22, 2016
Genome Diagnostics Laboratory, Amsterdam University Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Sep 21, 2015
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 30, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:4
Oct 22, 2015
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jun 13, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Apr 20, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

not specified Benign:2
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 23, 2015
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Jan 08, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.82
CADD
Benign
1.9
DANN
Benign
0.59
PhyloP100
-1.0
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs572846; hg19: chr11-66331458; COSMIC: COSV59747923; COSMIC: COSV59747923; API